Summary Both biodegradable emboli and pharmacological agents can enhance regional therapy for hepatic targeting. Using a rat model with similar haemodynamic characteristics to human colorectal liver tumour and a radio-labelled marker of similar molecular weight to Adriamycin, we have combined the two approaches to see if the effect was addictive.
Recent advances in chemotherapeutic treatment in patients with colorectal carcinoma either given in the presence of established metastases (Kemeny et al., 1987; Erlichman et al., 1988; Poon et al., 1989) or as an adjuvant treatment (Windle et al., 1987; Taylor et al., 1985; Moertel et al., 1990) , have resulted in both objective responses and small increases in survival. Regional chemotherapy aims to increase drug delivery to hepatic tumours and at the same time reduce systemic side effects. Hepatic arterial infusion is based on the rationale that the blood supply to hepatic metastases is derived principally from the hepatic artery with little contribution from the portal vein (Ensminger et al., 1978; Sigardson et al., 1986) . This approach has been associated with objective therapeutic responses, but has not yet resulted in an improvement in survival over systemic therapy in controlled clinical trials (Kemeny et al., 1987) . One possible explanation for the failure of regional therapy to improve survival is that many colorectal metastases are relatively hypovascular, the blood supply favouring delivery of drug to normal hepatic parenchyma.
Numerous vasoactive drugs have been used to manipulate hepatic and tumour blood flow and we have previously reported the effects of phenylephrine and angiotensin II on the distribution of a radio-labelled low molecular weight marker, 99ITc methylene diphosphonate (MDP), in an animal model (Hemingway et al., 1990) . We observed up to a 4-fold increase in the retention of marker in the tumour tissue relative to normal hepatic parenchyma at 1 min after injection. However, the vasoconstriction response was transitory and there was significant 'washout' of marker by 90 min. We have also used degradable starch microspheres (DSM) to manipulate drug delivery, and found a similar 4-fold retention in tumour at 1 min, but with less 'washout' at 90 min .
It is possible that these pharmacological and physical methods of enhancing second order targeting to liver tumour may act additively, and we report a series of experiments that have investigated this hypothesis.
Materials and methods
Animal model Liver tumours were induced in male Hooded Lister rats, weight 200-250 g, by a sub capsular injection of 106 HSN sarcoma cells. Three seeks after inoculation, overt liver tumours, weighing approximately 1-2 g, had developed at the sites of injection. Previous evaluation of the haemodynamic characteristics of this tumour model has shown that its blood supply is derived, as in metastatic colorectal tumours, almost entirely from the hepatic artery, the portal contribution being minimal. These tumours are relatively hypovascular compared to the surrounding normal liver with a tumour: liver hepatic arterial blood flow ratio of 0.6:1 (Hemingway et al., 1990) .
Tumour-bearing rats were anaesthetised by an intraperitoneal injection of sodium pentobarbitone (Sagatal 30 mg kg-1), and the gastroduodenal artery was cannulated. Care was taken to ensure that the tip of the cannula lay at the junction of the coeliac and hepatic arteries. A trial injection of saline ensured that the injectate flowed along the hepatic artery and not in a retrograde manner down the coeliac artery. The right common carotid artery was then cannulated for continuous measurement of systemic arterial blood pressure via a strain gauge transducer driving a pen recorder (Gould Medical, Lutterworth, UK).
Bloodflow manipulation A Pilot study (of three animals per group) compared: (a) DSM followed by angiotensin II and MDP; or (b) angiotensin II followed by DSM and MDP; (c) DSM, angiotensin II and MDP given simultaneously, was performed to ascertain the most effective mode of administration. The results of this study suggested that the most effective combination was achieved by the slow bolus injection of Angiotensin II, followed 1 min later by degradable starch microspheres (2 mg) and 30 lsl of MDP given over 30 s. This schedule was therefore used in the main comparative study. Study design Three experimental groups receiving regional delivery of 9'Tc labelled methylene diphosphonate (MDP), 100 MBq ml-', were compared. Control animals (two groups of nine) received in intraarterial injection of 30 of MDP in physiological saline over 30s. Two groups of animals (n = 12) were given a 20 IA intra-arterial injection of degradable starch microspheres (100 mg ml') mixed with 30 slI of 9'9Tc MDP as previously described .
In two further groups of experimental animals (12 per group) 50 gAl of angiotensin II (5 gsg ml-1) (Ciba-Geigy), was injected into the gastroduodenal artery over 30 s (Hemingway et al., 1990 
Results
Comparison of the three study groups using the KruskalWallis test confirmed that there was a significant difference in retention of marker in tumour (P = 0.003) and liver (P <0.001) at 1 min but only in tumour (P <0.001) and not liver (P = 0.21) by 90 min. Whereas there was no significant difference in the tumour:liver ratio at 1 min (P = 0.87) there was a significant difference by 90 min (P = 0.001). The results are summarised and detailed below in .
Discussion
Despite the accumulating clinical experience in the manipulation of hepatic arterial blood flow to optimise regional delivery Table I Retention Results are expressed as the median percentage of the injected dose per gram of tissue, the range in parenthesis. DSM or DSM/AII vs control (Mann-Whitney): *P <0.05, **P <0.01, ***P <0.001.
DSM/ALL vs DSM: ItP<0.01, ttt P<0.001.
-4-to tumour tissue, the rationale for using degradable emboli or vasoactive agents for regional tumour targeting has not been fully evaluated at an experimental level. Tumour vessels are immature and, lacking muscular elements, are therefore unable to react to vasoconstricting agents (Mattson et al., 1977; Mattson et al., 1978) . Any response therefore occurs predominantly in the normal hepatic parenchyma inducing a temporary relative tumour hypervascularity favouring the delivery of administered agent to tumour rather than normal liver.
Using the HSN sarcoma cell model of colorectal metastases we have previously shown that both phenylephrine and angiotensin II will increase the delivery of marker to tumour 4-fold over controls although the effect is transitory (Hemingway et al., 1990) . This study has also confirmed our previous report that DSM can significantly increase the retention of marker within tumour . All animals studied had on average a 12-fold increase in retention of marker compared to controls at 1 min after injection. In contrast to our earlier reported studies we have failed to confirm an immediate preferential delivery to hepatic tumour. We previously suggested that the increased retention of marker was due to a redistribution of intrahepatic blood diverting flow marker away from normal hepatic parenchyma towards hepatic tumour. The results from this study however would suggest that the DSM is distributed according to blood flow which initially results in a similar tumour to liver ratio as control animals. The relatively greater retention within tumour tissue, with almost complete washout of marker from normal liver tissue at 90 min, is probably the result of continued portal washout in normal hepatic parenchyma, which is not present in tumour.
Angiotensin II results in redistribution of intrahepatic arterial flow towards tumour tissue (Hemingway et al., 1990) . In this experiment the administration of Angiotensin II immediately prior to the regional injection of DSM may therefore result in preferential delivery of both DSM and marker to tumour tissue. Whilst there was no immediate advantage for the combination of DSM and angiotensin II over DSM alone, there was an advantage at 90 min with significantly greater retention of marker in tumour tissue compared to DSM alone and a 12-fold increase compared to the value in control animals. Moreover, the tumour:liver ratio of retained marker was significantly improved using combined angiotensin II and DSM with a concentration of marker in tumour over five times that in normal hepatic parenchyma. The maintenance of relatively high marker concentration in tumour over a 90 min period may reflect blood flow stasis and further prevention of washout, due to targeting of the DSM toward the tumour by the Angiotensin II.
Both Angiotensin II and DSM have been used independently to improve regional delivery of chemotherapeutic drugs in clinical trials in patients with colorectal metastases (Civellari et al., 1985; Goldberg et al., 1990; Hunt et al., 1990) . The results of this study would suggest that a combination of Angiotensin II and DSM may further improve the delivery of drug to hepatic tumour, whilst minimising exposure of normal hepatic parenchyma to potentially hepatotoxic drugs.
